On Monday, Stratasys, Ltd. (NASDAQ:SSYS)’s shares declined -2.45% to $37.06.
MakerBot, a global leader in the desktop 3D printing industry, and Stratasys AP Ltd, a partner of MakerBot’s parent company Stratasys Ltd. ( SSYS), a leading global provider of 3D printing and additive manufacturing solutions, recently declared the strengthening of MakerBot’s market presence in Asia Pacific through MakerBot Asia Pacific & Japan (MakerBot APJ), a new MakerBot division to capture the growth potential of desktop 3D printers and scanners in the region. Stratasys has a strong presence in the region and MakerBot APJ aims to leverage on the existing Stratasys infrastructure to strengthen its local operations and expand availability of its products. MakerBot APJ will continue to support the existing MakerBot network of distributor and reseller partners in Asia Pacific.
Stratasys has 10 regional offices to serve its customers in Asia Pacific, counting the Asia Pacific headquarters in Hong Kong and presences in Shanghai, Beijing, Shenzhen, Tokyo, Osaka, Seoul, Busan, Singapore and Bangalore. These Stratasys offices will support MakerBot’s local business operations with marketing, sales and customer support initiatives. MakerBot APJ will be led by Shiry Saar, who has been designated General Manager and is based in Stratasys’ Asian headquarters in Hong Kong, operating under Stratasys AP Ltd. Saar had served in several administration roles at Stratasys formerly.
Stratasys Ltd. provides additive manufacturing (AM) solutions for the creation of parts used in the processes of designing and manufacturing products; and for the direct manufacture of end parts. Its AM systems utilize its patented fused deposition modeling and inkjet-based PolyJet technologies to enable the production of prototypes, tools used for production and manufactured goods directly from three-dimensional (3D) CAD files or other 3D content. The company offers entry-level desktop 3D printers for idea and design development, a range of systems for rapid prototyping, and production systems for direct digital manufacturing under the Dimension, Objet, Fortus, Polyjet, SolidScape, and MakerBot brands.
Energy Transfer Equity LP (NYSE:ETE)’s shares dropped -0.19% to $67.78.
Energy Transfer Equity LP (ETE) offered further details on its formerly declared Revolution Project that will significantly enhance its operations in the growing Marcellus and Upper Devonian production areas of Western Pennsylvania. ETP has reached long-term gas gathering, processing, and fractionation agreements with EdgeMarc Energy. To facilitate these agreements, ETP has purchased about twenty miles of high pressure pipeline from EdgeMarc and will build a new cryogenic gas processing plant, a new fractionators and additional gas gathering pipelines.
ETP plans to construct about 100 miles of high pressure 24- and 30-inch rich gas pipeline providing a total gathering system capacity in excess of 440 million cubic feet per day. The Revolution Pipeline originates in Butler County, Pennsylvania and will extend to ETP’s Revolution Plant, a new cryogenic gas processing plant to be constructed in Western Pennsylvania. The Revolution Plant is predictable to be in-service by the second quarter of 2017 and will allow for future processing growth for additional third party gas.
Energy Transfer Equity, L.P., through its auxiliaries, provides diversified energy-related services in the Unites States. It owns and operates about 7,700 miles of natural gas transportation pipelines and 3 natural gas storage facilities located in the state of Texas; and about 12,800 miles of interstate natural gas pipeline. The company sells natural gas to electric utilities, independent power plants, local distribution companies, industrial end-users, and other marketing companies. Its midstream operations owns and operates about 7,200 miles of in service natural gas and natural gas liquid (NGL) gathering pipelines, 6 natural gas processing plants, 15 natural gas treating facilities, and 3 natural gas conditioning facilities.
At the end of Monday’s trade, Neurocrine Biosciences, Inc. (NASDAQ:NBIX)‘s shares surged 4.07% to $45.28.
Neurocrine Biosciences, Inc. (NBIX) declared that it has suspended two planned clinical studies of the Company’s CRF antagonist NBI-77860.
The two clinical studies that were halted comprise a single dose study in adolescent females with classic congenital adrenal hyperplasia and a multiple dose study in adults with classic congenital adrenal hyperplasia. The Company had not enrolled any subjects in either study and accordingly, there have been no adverse events stated.
The Company has also been informed by the FDA that the NBI-77860 clinical development program would be placed on partial clinical hold.
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company’s products in clinical development stage comprise elagolix, which is in Phase III study for endometriosis; elagolix that is in Phase IIb study for uterine fibroids; Corticotropin-Releasing Factor Receptor1 Antagonist, which is in Phase I/II study for congenital adrenal hyperplasia and stress-related disorders; and Vesicular Monoamine Transporter 2 Inhibitor (VMAT2) that is in Phase III study for movement disorders, in addition to Phase I study for tourette syndrome. Its research programs comprise VMAT2 for movement disorders, bipolar disorders, and schizophrenia; gonadotropin-releasing hormone (GnRH) antagonists for men’s and women’s health, and oncology; antiepileptic drugs for epilepsy, essential tremor, and pain; and G Protein-Coupled receptors for other conditions.
Cytori Therapeutics Inc (NASDAQ:CYTX), ended its Monday’s trading session with -1.45% loss, and closed at $0.652.
Cytori Therapeutics Inc (CYTX) reached a four year, $17.7 million term loan with Oxford Finance LLC. The loan provides for an interest-only payment period of at least 12-months with the potential to be extended up to 18-months. Proceeds were used to prepay Cytori’s existing loan with Oxford Finance LLC and Silicon Valley Bank. The loan was funded in full on May 29, 2015 and matures June 1, 2019.
Select terms of the loan comprise the following:
- Interest rate of 8.95% (comprised of three-month LIBOR rate with a floor of 1.00% plus 7.95%) contrast with 9.75% under the prior loan
- Interest-only payments for 12-months followed by 36 equal monthly principal and interest payments
- The interest-only payment period may be extended by six months through December 2016 should Cytori achieve positive US ACT-OA clinical trial data or close a licensing, partnership or similar transaction on terms acceptable to the lenders by May 31, 2016
Cytori Therapeutics, Inc., a biotechnology company, develops cell therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy comprising of a heterogeneous population of specialized cells, counting stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
